RASSF6 is a member of the tumor suppressor Ras-association domain family (RASSF) 37 proteins. RASSF6 is frequently suppressed in human cancers and its low expression is 38 associated with poor prognosis. RASSF6 regulates cell cycle arrest and apoptosis and 39 plays a tumor suppressor role. Mechanistically, RASSF6 blocks MDM2-mediated p53 40 degradation and enhances p53 expression. However, RASSF6 also induces cell cycle 41 arrest and apoptosis in the p53-negative background, which implies that the tumor 42 suppressor function of RASSF6 does not depend solely on p53. In this study, we have 43 revealed that RASSF6 mediates cell cycle arrest and apoptosis via pRb. RASSF6 44 enhances the interaction between pRb and protein phosphatase. RASSF6 also enhances 45 P16INK4A and P14ARF expression through suppressing BMI1. In this way, RASSF6 46 increases unphosphorylated pRb and augments the interaction between pRb and E2F1. 47
146
RASSF6 promotes the interaction between pRb and protein phosphatases 147 pRb phosphorylation is regulated by protein phosphatases (PP1A and PP2A) (35). In 148 Drosophila melanogaster, dRASSF, a fly homologue of RASSF, interacts with fly 149 homologues of components of the striatin-interacting protein phosphatases and kinases 150 (STRIPAK) complexes (36) . STRIPAK is a complex of PP2A that interacts with Ste20-151 like kinases (37). In mammals, although the direct interaction between RASSF and 152 STRIPAK complex is not reported, RASSF proteins are detected in the interactome of 153 MST kinases and STRIPAK complex (38) . We hypothesized that RASSF6 promotes as a 154 scaffold the interaction between pRb and protein phosphatases and facilitates 155 dephosphorylation of pRb. We immunoprecipitated RASSF6 from human colon cancer 156 SW480 cells and detected the co-immunoprecipitated pRb with RASSF6 ( Fig. 3A, an  157 arrow). To further confirm the interaction, we exogenously expressed RASSF6 and pRb 158 in HEK293FT cells and performed the co-immunoprecipitation experiment. When 159 FLAG-RASSF6 was immunoprecipitated, V5-pRb was co-immunoprecipitated ( Fig. 3B,  160 the left). In the reverse experiment, FLAG-RASSF6 was co-immunoprecipitated with V5-161 pRb (Fig. 3B, the right) . In the experiment shown in Fig 2C, we noted that RASSF6, 162 when co-expressed with pRb, was recovered not only in the cytoplasm but also in the 163 nucleus ( Fig. 2C , the second panel). This observation prompted us to ask whether pRb 164 affects the subcellular localization of RASSF6. We expressed FLAG-RASSF6 with or 165 without V5-pRb in HeLa cells and evaluated the subcellular localization in the 166 immunofluorescence and in the subcellular fractionation ( Fig. 3C and 3D ). FLAG-167 RASSF6 was distributed mainly in the cytoplasm (Fig. 3C , the upper panel, and Fig. 3D ). 168
However, when co-expressed with V5-pRb, FLAG-RASSF6 was detected in the nucleus 169 ( Fig. 3C, the lower panel) . The subcellular fractionation also supported that pRb 170 increased the nuclear RASSF6 ( Fig. 3D , an arrow). We next examined the effect of 171 RASSF6 on the interaction between protein phosphatases and pRb. We expressed 172 luciferase-fused PP1A and PP2A with V5-pRb in HEK293FT cells and 173 immunoprecipitated V5-pRb. The luciferase activity in the immunoprecipitates was 174 measured to evaluate the co-immunoprecipitation of PP1A and PP2A with pRb. RASSF6 6 / 27 pRb with protein phosphatases allowing pRb to remain unphosphorylated. RASSF5 178 promotes dephosphorylation of pRb (39) . RASSF1A blocks dephosphorylation of 179 mammalian Ste20-like kinases (MST1 and -2) (40). As RASSF1A and RASSF5 can 180 interact with RASSF6 (41) , it is possible that RASSF6 regulates the phosphorylation 181 state of pRb and the interaction of pRb with E2F1 through RASSF1A and RASSF5. 182 However, neither RASSF1 silencing nor RASSF5 silencing had no effect on the RASSF6-183 mediated suppression on E2F1 promoter reporter, which means that RASSF6 regulates 184 pRb independently of RASSF1A and RASSF5 (Suppl. Fig. 1 ). As pRb and MDM2 interact 185 with each other (42), we examined whether and how pRb affects the interaction between 186 RASSF6 and MDM2. However, pRb did not show any effect (Suppl. Fig. 2 ). 187 188 RASSF6 induces CDKN2A independently of p53.
189
Another explanation of the reduced phosphorylation of pRb is the inhibition of CDKs. As 190 RASSF6 enhances p53 expression, it is reasoned that RASSF6 up-regulates CDKN1A 191 (cyclin-dependent kinase inhibitor 1A) mRNA via p53, and inhibits the CDK2/4-192 mediated phosphorylation of pRb via CDKN1A. However, in this study, we want to know 193 how RASSF6 functions as a tumor suppressor in the p53-negative background. We 194 therefore examined whether RASSF6 regulates CDKN1A and CDKN2A in HCT116 p53-195 /-cells. The treatment with doxorubicin enhance P16INK4A and P14ARF, both of which 196 are encoded in CDKN2A locus, at the mRNA level ( Fig. 4A, siCont. ). RASSF6 depletion 197 abolished the enhancement of P16INK4A and P14ARF (Fig. 4A, siRASSF6#1 ).
198
Doxorubicin, although to a lesser extent, enhanced CDKN1A in HCT116 p53-/-cells, but 199 RASSF6 silencing had no effect on the enhancement of CDKN1A (Fig. 4A The next question is the mechanism by which RASSF6 enhances P16INK4A and 207 P14ARF. As polycomb complex protein BMI1 is well-known to down-regulate P16INK4A 208 and P14ARF expression, we suspected the implication of BMI1 (43). We examined 209 whether BMI1 silencing antagonized RASSF6 silencing. As expected, the additional 210 knockdown of BMI1 recovered the enhancement of P16INK4A and P14ARF in RASSF6-211 depleted cells (Fig. 4A, siRASSF6#1+siBMI1 ). This observation supports that RASSF6 212 antagonizes BMI1 in the regulation of P16INK4A and P14ARF. RASSF6 expression did 7 / 27 not affect BMI1 mRNA expression (data not shown). We next tested whether and how 214 RASSF6 affects BMI1 at the protein level. First, we tested the interaction between 215 RASSF6 and BMI1. BMI1 was co-immunoprecipitated with RASSF6 from SW480 cells 216 ( Figure 4B , an arrow). We could also detect the interaction between exogenously 217 expressed RASSF6 and BMI1 (Fig. 4C , the right and the left). We next examined the 218 effect of RASSF6 on the stability of BMI1. We first confirmed that the cycloheximide 219 treatment induced the mobility shift of BMI1 as previously reported (Fig. 4D , the first 220 and second lanes) (44). RASSF6 silencing increased the upward shifted band (Fig. 4D , 221 the third lane, an arrow). The treatment with  phosphatase abolished this shift (Fig. 222 4D, the fourth lane). These findings support that cycloheximide induces the 223 phosphorylation of BMI1 and that RASSF6 silencing increases it. We next evaluated 224 BMI1 degradation in the presence of RASSF6 ( Fig. 4E ). GFP-RASSF6 slightly reduced 225 BMI1 protein expression ( Fig. 4E , 0 h). More remarkably, RASSF6 decreased the 226 upward-shifted BMI1 ( Fig. 4E , 3 h to 12 h). TrCP regulates BMI1 ubiquitination and 227 degradation (44). We next examined the effect of RASSF6 silencing on BMI1 stability in 228 the presence of TrCP. RASSF6 silencing increased the up-ward shifted BMI1 and 229 delayed its degradation (Fig. 4F , the right). Moreover, RASSF6 silencing reduced BMI1 230 polyubiquitination ( Fig. 4G ). We also examined the subcellular distribution of RASSF6 231 and BMI1 (Suppl. Fig. 3 ). RASSF6 did not affect the subcellular localization, but reduced 232 BMI1 expression. BMI1 did not affect the subcellular localization of RASSF6, either. All 233 these findings support that RASSF6 promotes the degradation of BMI1, which may 234 contribute the enhancement of P16INK4A and P14ARF. 235 236 pRb is involved in RASSF6-induced apoptosis. 237
In certain circumstances, pRb is involved in apoptosis (45). For instance, in prostate 238 cancer cells, cell detachment increases unphosphorylated pRb and induces apoptosis (46). 239
Moreover, under DNA damage, pRb is dephosphorylated at CDK-mediated 240 phosphorylation sites but phosphorylated by checkpoint kinases (47). Phosphorylated 241 pRb binds to E2F1 and enhances pro-apoptotic genes (47). We first raised a question 242 whether pRb is involved in RASSF6-induced apoptosis. We expressed GFP-RASSF6 in 243 HCT116 p53-/-cells. GFP-RASSF6 caused nuclear condensation and induced 244 cytochrome-C release (Fig. 5A , siCont., GFP-RASSF6, arrows). RB1 silencing decreased 245 nuclear condensation and cytochrome-C release (Fig. 5A, siRB1#1 and siRB1#2, GFP-246 RASSF6, arrowheads). In DNA content analysis by flow cytometry, GFP-RASSF6 247 increased sub-G1 population (Fig. 5B , siCont., GFP and GFP-RASSF6). RB1 silencing, 8 / 27 however, reduced sub-G1 population in RASSF6-expressing cells (Fig. 5B , siCont and 249 siRB1#1, GFP-RASSF6). These findings support that pRb is involved in induced apoptosis in the p53-negative background. 251 252 E2F1 is involved in RASSF6-induced apoptosis 253 E2F1 regulates a wide variety of genes involved in not only proliferation but also 254 apoptosis (48). For instance, E2F1 regulates apoptosis-related genes such as APAF1 and 255 CASPs (49, 50) . pRb recruits histone deacetylases to repress classic E2F1 target genes 256 such as CCNA2, but in cells exposed to DNA damage, pRb forms a transcriptionally 257 active complex including E2F1 and P/CAF to promote transcription of pro-apoptotic 258 genes such as TP73 and CASP7 (47, 51, 52) . To determine whether E2F1 is involved in 259 RASSF6-induced apoptosis, we examined the effect of E2F1 silencing. E2F1 silencing 260 attenuated RASSF6-induced nuclear condensation and cytochrome-C release in 261 RASSF6-expressing HCT116 p53-/-cells ( Fig. 6A ). To more directly confirm that 262 RASSF6 plays a role in pRb/E2F1-mediated transcription of pro-apoptotic genes, we 263 quantified mRNAs of TP73, CASP7, and BAX. RASSF6 increased pro-apoptotic TP73, 264 CASP7, and BAX, but had no effect onCCNA2. (Fig. 6B , siCont, gray and black bars).
265
However, RB1 silencing and E2F1 silencing abolished the effect of RASSF6 ( Fig. 6B , 266 siRB1#1 and siE2F1). These findings support that E2F1 is involved in RASSF6-induced 267 apoptosis. Although YAP1, a target of the Hippo pathway, co-operates with p73, YAP1 268 silencing had no effect on RASSF6-mediated apoptosis in HCT116 p53-/-cells (Suppl. 269 Fig. 4 ). BMI1 silencing did not augment RASSF6-indced apoptosis, either (Suppl. Fig. 5 ).
270

RASSF6 depletion impairs DNA repair and causes genomic instability 272
In the previous study, we demonstrated that RASSF6 depletion impairs DNA repair in 273 HCT116 cells and results in the generation of polyploid cells (14). To evaluate the 274 significance of RASSF6 as a tumor suppressor in the p53-negative background, we 275 examined the effect of RASSF6 depletion on DNA repair in HCT116 p53-/-cells. After 3 276 h-treatment with VP-16, H2A.X signals appeared ( Fig. 7A , HCT116 p53+/+, 0 h) but 277 disappeared within 3 h after the removal of VP-16 in HCT116 p53+/+ cells ( Fig. 7A , 278 HCT116 p53+/+, 3 h). However, in HCT116 p53-/-cells, the signals remained up to 9 h 279 ( Fig. 7A, HCT116 p53-/-, siCont, 9 h). This means that DNA repair is delayed in HCT116 280 p53-/-cells. Even so, H2A.X signals decreased in the time-dependent manner and 281 became barely detectable 21 h later ( Fig. 7A, HCT116 p53-/-, siCont, 21 h). However, 9 / 27 HCT116 p53-/-, siRASSF6#1, 21 h). These findings support that RASSF6 is necessary 284 for DNA repair in the p53-negative background. We cultured VP-16-treated HCT116 285 p53-/-cells for 96 h and analyzed DNA content by FACS. The polyploid cells were 286 increased by the treatment with VP-16 ( Fig. 7B , siCont, 1.64 % vs 13.03 %). RASSF6 287 depletion further increased the polyploid cells ( Fig. 7B , VP-16, siRASSF6#1 and 288 siRASSF6#2). All these findings support the possibility that RASSF6 plays a tumor 289 suppressor role in cancer cells with dysregulated p53 290 291 DISCUSSION 292 RASSF6 is one of the classical RASSF proteins, the proteins that have the Ras-293 association domains in the C-terminal region, and co-operates with the well-conserved 294 tumor suppressor Hippo pathway (41). The low expression of RASSF6 is observed in 295 human cancers and correlates with the shortened disease-free survival, which 296 corroborates that RASSF6 plays a tumor suppressive role in human. Forced expression 297 of RASSF6 induces apoptosis and cell cycle arrest in various cells (11, 12) . p53 depletion 298 attenuates RASSF6-induced apoptosis and overcomes RASSF6-induced cell cycle arrest, 299 which supports that p53 functions down-stream of RASSF6 (14). In fact, RASSF6 300 interacts with MDM2 and blocks MDM2-mediated degradation of p53. RASSF6 301 depletion suppresses ultraviolet exposure-induced p53 target gene expression. KRAS 302 strengthens the interaction between RASSF6 and MDM2, and causes apoptosis 303 depending on p53 (19) . In this respect, MDM2-p53 is important for the tumor suppressor 304 role of RASSF6. However, p53 depletion does not completely abolish RASSF6-mediated 305 apoptosis (14). Moreover, RASSF6 induces apoptosis in p53-negative HCT116 cells. 306
These findings imply that RASSF6 causes apoptosis independently of p53. This 307 observation is important, because it means that RASSF6 works as a tumor suppressor 308 in cancers with p53 mutations. In this line, we have studied the molecular mechanism 309 underlying the p53-independent tumor suppressor role of RASSF6. 310 RB1 is the first identified tumor suppressor gene and its defects cause many 311 human cancers (23). A recent report has revealed that Nore1A (a splicing variant of 312 RASSF5) forms a complex composed of protein phosphatase 1A and pRb to promote pRb 313 dephosphorylation and to mediate Ras-induced senescence (39). Based on these data, we 314 examined the relations of RASSF6 and pRb. To accentuate the role of pRb, we used 315 HCT116 p53-/-cells in this study. First, we confirmed that RB1 silencing attenuates 10 / 27 (20, 26) . When pRb is phosphorylated by CDKs, it fails to bind the E2F proteins, so that 319 cells proceed from G1 to enter S. During M to G1, pRb is dephosphorylated by protein 320 phosphatases and returns to the unphosphorylated form (35) . As RASSF6 blocks the 321 DNA synthesis depending on pRb ( Fig. 1) and Nore1A promotes pRb dephosphorylation 322 (39), we suspected that RASSF6 as well suppresses the phosphorylation of pRb. As 323 expected, RASSF6 reduces the phosphorylation at serine-608 and at threonine-821, both 324 of which destabilize the interaction between pRb and E2F (Fig. 2) . Accordingly, RASSF6 325 strengthens the binding of pRb to E2F1 and suppresses E2F1 promoter reporter 326 depending on pRb ( Fig. 2D and 2E ). Conversely, RASSF6 silencing enhanced E2F1 327 promoter reporter (Fig. 2F) . A kinase shRNA screening revealed that LATS2 promotes 328 the assembly of DREAM repressor complex and suppresses E2Ftarget genes (34). As 329 RASSF6 cross-talks with the Hippo pathway, it is reasonable to question whether LATS2 330 is implicated in RASSF6-mediated suppression of E2F1 reporter activity. However, 331 LATS1/2 silencing had no effect ( Fig. 2G ). Moreover, LIN52 silencing did not affect 332 RASSF6-mediated repression, either (Fig. 2H ). These findings suggest that RASSF6 333 repress E2F1-mediated transcription independently of DREAM repressor complex. 334
Likewise, YAP1 silencing did not show any effect on RASSF6-mediated apoptosis (Suppl. 335 Fig. 4 ). This result is comprehensible, because RASSF6 plays a tumor suppressor role 336 independently of the Hippo pathway (12). 337
As reported for Nore1A, RASSF6 increases the interaction between pRb and 338 protein phosphatases. RASSF6 and pRb were co-immunoprecipitated ( Fig. 3A and 3B ). 339 pRb recruited RASSF6 into the nucleus ( Fig. 3C and 3D ). These findings support that 340 RASSF6 and pRb interact with each other. Considering that proteomic analysis revealed 341 RASSF proteins in the interactome of MST kinases and STRIPAK complex, we 342 speculated that RASSF6 may link protein phosphatases to pRb. Indeed, RASSF6 343 promoted the binding of PP1A and PP2A to pRb (Fig. 3E ). RASSF6 interacts with other 344 RASSF proteins (41). RASSF5 promotes dephosphorylation of pRb via PP1A (39).
345
RASSF1A conversely blocks PP1-and PP2A-mediated dephosphorylation of mammalian 346 Ste20-like kinase 1 and -2 (40). Therefore, it is possible that RASSF6 modulates 347 phosphorylation of pRb via RASSF1A and RASSF5. However, RASSF1 silencing or 348 RASSF5 silencing did not affect the inhibitory effect of RASSF6 on E1F1 promoter 349 reporter, which indicates that RASSF6 regulates pRb independently of RASSF1 or 350 RASSF5 (Suppl. Fig 1) .
/ 27
suppresses P16INK4A and P14ARF. Serine 110 phosphorylation is known to stabilize 354 BMI1 (53). It is considered that RASSF6 promotes dephosphorylation of BMI1 and 355 destabilizes it. We also observed that CDKN1A expression was enhanced by doxorubicin 356 in HCT116 p53-/-cells, which is consistent with a previous report (54) but that RASSF6 357 silencing had no effect on CDKN1A. In that paper, the researchers demonstrated the 358 implication of p63. Thus, the induction of CDKN1A by doxorubicin in HCT116 p53-/-359 cells may be independent of RASSF6. In short, RASSF6 reduces the phosphorylation of 360 pRb in two ways; through the promotion of dephosphorylation and the inhibition of 361 phosphorylation by CDKs (Fig 8) . 362 In cells exposed to DNA damage such as doxorubicin treatment, phosphorylated 363 pRb forms a complex with E2F1 (47). DNA damage triggers the binding of histone 364 acetyltransferase to E2F1 and the acetylation of E2F1 and promotes the association of 365 E2F1 with the promoters of proapoptotic genes. Therefore, we examined whether pRb 366 and E2F1 are implicated in RASSF6-induced apoptosis. The silencing of RB1 or E2F1 367 suppresses RASSF6-induced apoptosis ( Fig. 5 and Fig. 6 ). RASSF6 expression enhances 368 proapoptotic genes including TP73, CASP7, and BAX, while the silencing of RB1 or E2F1 369 blocks the effect of RASSF6 (Fig. 6 ). We previously observed that TP73 silencing did not 370 attenuate RASSF6-induced apoptosis in HCT116 p53+/+ cells (14) . Therefore, the 371 enhancement of TP73 by RASSF6 was unexpected. However, it is discussed that p73 372 functionally replaces p53 in p53-deficient cells (55) . As we used HCT116 p53-/-cells in 373 this study, we speculate that the transcriptional regulatory networks may be changed by 374 p53 depletion in these cells. 375
In the final set of the experiments, we showed that RASSF6 depletion impairs 376 DNA repair in the p53-negative cells (Fig. 7) . RASSF6 depletion also increases the 377 generation of polyploid cells. These findings suggest that RASSF6 is a significant tumor 378 suppressor in p53-compromized cells. Of note, RB1 silencing does not completely abolish 379 RASSF6-induced apoptosis in p53-negative cells (Fig. 5 ). RASSF6 induces apoptosis and 380 suppresses proliferation in Saos-2 cells, which have TP53 mutation and RB1 mutation 381 (data not shown). These findings mean that there should be a certain mechanism by 382 which RASSF6 works as a tumor suppressor independently of both p53 and pRb. The 383 dissection of such a mechanism will also be the subject of the next project. The reporter assay was performed as described for Figure 2E . ***, p<0.001. 731 (G) HEK293FT cells were transfected with LATS1 and LATS2 siRNAs. The reporter 732 assay was performed as described for Figure 2E or pCIneoGFP-RASSF6 (GFP-RASSF6). Apoptosis was evaluated as described for 817 Figure 5A . Data indicate the mean with S.D. ***, p<0.001. Scale bars, 10 m. 818 (B) HCT116 p53-/-cells were transfected with control siRNA, RB1 siRNA#1, or E2F1 819 siRNA. 48 h later, the cells were transfected with control pCIneoGFP or pCIneoGFP-820 RASSF6. 24 h later, the cells were harvested and mRNAs were collected. qRT-PCR 821 was performed by use of glyceraldehyde-3-phosphate dehydrogenase as a reference. 822
The value for the cells expressing control GFP was set at 1.0. Data indicate the mean 823 with S.D. for the triplicate samples. TP73, CASP7, and BAX genes were up-regulated 824 by RASSF6. RB1 or E2F1 knockdown abolished the effect of RASSF6. CCNA2 gene 825 was not enhanced by RASSF6. ***, p<0.001; and n.s., not significant. 826 827 Figure 7 . RASSF6 depletion delays DNA repair and increases polyploid cells in the p53-828 negative background. 829 HCT116 p53+/+ cells were exposed to 50 M VP-16 for 3 h and then VP-16 was removed. 830
The cells were harvested at the indicated time points and H2A.X was immunostained. 831
The scheme of the protocol was demonstrated on the top in (A). HCT116 p53-/-cells were 832 transfected with control siRNA or RASSF6 siRNA (#1 in (A); #1 and #2 in (B)). 48 h later, 833 the cells were exposed to 50 M VP-16 for 3 h and then VP-16 was removed. In (A), 834 thereafter, H2A.X was immunostained at the indicated time points (0 h means 835 "immediately after 3 h-treatment with VP-16") and H2A.X was immunostained. 500 836 cells were observed for each sample and H2A.X-positive cells were counted. The bar 837 graphs are the summary of three independent experiments. Data indicate the mean with 838 S.D. ***, p<0.001. Scale bars, 20 m. In (B), the cells were cultured for 96 h after removal 839 of VP-16, and DNA contents were evaluated by use of FACS. VP-16 treatment induced 840 polyploid cells, and RASSF6 depletion further increased them. 841 842 Figure 8 . The mechanism by which RASSF6 keeps pRb unphosphorylated. 843 RASSF6 links protein phosphatases to pRb and promotes dephosphorylation of pRb. 844 RASSF6 also reduces the phosphorylated form of BMI1, which is resistant against 
